Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Virginie Gandemer, MD, Marie-Françoise Auclerc, MD, Arnaud Petit, MD, Benoît Brethon, MD, Paola Ballerini, Gerard Michel, MD, PhD, Yves Perel, MD, PhD, Anne Auvrignon, MD, Francoise Mechinaud, Claudine Schmitt, Pascale Schneider, Christiane Vermylen, Odile Lejars, MD, Thierry Leblanc, MD, Jean Gabert, MD, PhD, Elizabeth Macintyre, MD, PhD, Jean-Michel Cayuela, PharmD, PhD, Guy Leverger, MD, Andre Baruchel, MD

Blood (2009) 114 (22): 1628.

https://doi.org/10.1182/blood.V114.22.1628.1628

Published: 2009

Journal Articles

Improved Prognosis of Children and Adolescents with Acute Lymphoblastic Leukemia (ALL) and Very-High Minimal Residual Disease (MRD) and the End of Induction therapy (EOI)? Preliminary Results of the FRALLE 2000 Protocol

Jean-Michel Cayuela, Kheira Beldjord, Sylvie Fasola, Marie-Françoise Auclerc, MD, Benoît Brethon, Anne Auvrignon, Francoise Mechinaud, Virginie Gandemer, MD, Geneviève Margueritte, Pascale Blouin, Nathalie Grardel, Hélène Cavé, Elizabeth Macintyre, Leverger Leverger, MD, PhD, Andre Baruchel, MD

Blood (2008) 112 (11): 2541.

https://doi.org/10.1182/blood.V112.11.2541.2541

Published: 2008

Journal Articles

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Blood (2008) 112 (11): 10.

https://doi.org/10.1182/blood.V112.11.10.10

Published: 2008

Journal Articles

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Blood (2007) 110 (11): 1427.

https://doi.org/10.1182/blood.V110.11.1427.1427

Published: 2007

Journal Articles

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Andre Baruchel, MD, Marie-Françoise Auclerc, MD, Yves Perel, MD, Françoise Mechinaud, MD, Anne Auvrignon, MD, Claudine Schmitt, MD, Christophe Piguet, MD, Odile Lejars, MD, Christian Berthou, MD, François Demeocq, MD, Pascale Schneider, MD, Virginie Gandemer, MD, Gérard Michel, MD, Jean-Michel Cayuela, Pharm D, Thierry Leblanc, MD, Guy Leverger, MD, the FRALLE Group

Blood (2006) 108 (11): 1852.

https://doi.org/10.1182/blood.V108.11.1852.1852

Published: 2006

Journal Articles

Cerebral Thromboses during Treatment of Childhood Acute Lymphoblastic Leukaemia.

Brigitte Pautard, Julie Micheli, Marie-Françoise Auclerc, Valérie Li Thiao Te, Thierry Leblanc, Barbara Horle, Judith Landman Parker, Claudine Schmitt, Gérard Michel, Pascale Schneider, Geneviève Margueritte, Anne Notz, Virginie Gandemer, Guy Leverger, André Baruchel

Blood (2005) 106 (11): 876.

https://doi.org/10.1182/blood.V106.11.876.876

Published: 2005

Journal Articles

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

André Baruchel, MD, Sylvie Chevret, MD, PhD, Anne Auvrignon, MD, Paola Ballerini, MD, PhD, Gérard Michel, MD, Jean Gabert, MD, PhD, Christiane Vermylen, MD, Yves Perel, MD, Chrystèle Bilhou-Nabera, MD, Odile Lejars, MD, Claudine Schmitt, MD, Pierre Jonveaux, MD, PhD, Jean Soulier, MD, PhD, Jacqueline Vandenaker, MD, Marie-Françoise Auclerc, MD, Thierry Leblanc, MD, Guy Leverger, MD, for the FRALLE Group

Blood (2005) 106 (11): 1441.

https://doi.org/10.1182/blood.V106.11.1441.1441

Published: 2005

Journal Articles

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1105.

https://doi.org/10.1182/blood.V104.11.1105.1105

Published: 2004

Journal Articles

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Blood (2004) 104 (11): 1952.

https://doi.org/10.1182/blood.V104.11.1952.1952

Published: 2004

NARROW

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Improved Prognosis of Children and Adolescents with Acute Lymphoblastic Leukemia (ALL) and Very-High Minimal Residual Disease (MRD) and the End of Induction therapy (EOI)? Preliminary Results of the FRALLE 2000 Protocol

High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Cerebral Thromboses during Treatment of Childhood Acute Lymphoblastic Leukaemia.

A Plateau after 30 Months of Follow-Up in B -Lineage Childhood Acute Lymphoblastic Leukemia (ALL) with t(1;19)(q23;p13)/E2A-PBX1?.

Minimal Residual Disease (MRD) at the End of Induction (EOI) after a Three or Four-Drug Induction Regimen for Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Interim Results of the FRALLE 2000-A Protocol.

Childhood Standard-Risk B-Cell Precursor Acute Lymphoblastic Leukemia (SR-BCP-ALL): Toxicity and Efficacy Interim Results of the FRALLE 2000-A Protocol.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only